GP
GILD icon

GLR Partners’s Gilead Sciences GILD Stock Holding History

GLR Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$493K Buy
3,904
+156
+4% +$20.6K 0.23% 68
2026
Q1 		$522K Buy
+3,748
New +$525K 0.29% 59

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GLR Partners's GILD Position: Q2 2026 in Review

GLR Partners increased its Gilead Sciences (GILD) stake by 4.2% in Q2 2026, buying an estimated $20.6K and bringing the position to 3,904 shares worth $493K. The position accounts for 0.23% of the portfolio, ranked #68.

GLR Partners first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $522K in Q1 2026. 2,262 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • GLR Partners held 3,904 shares of Gilead Sciences worth $493K as of Q2 2026.
  • GLR Partners bought 156 Gilead Sciences shares in Q2 2026, an estimated $20.6K.
  • Gilead Sciences made up 0.23% of GLR Partners's portfolio in Q2 2026, its #68 holding.
  • GLR Partners first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • GLR Partners's Gilead Sciences position peaked at $522K in Q1 2026.
  • 2,262 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on GLR Partners's 13F filing for Q2 2026, filed 27 Jul 2026.